Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Snapping Up US Mitochondrial Disease Specialist Mitobridge
December 5, 2017
- Takeda Officially Organizes “Shonan Health Innovation Park”; Ex-Lilly Japan R&D Chief to Wield the Baton
December 5, 2017
- Daiichi Sankyo Winds Up Deal on Thrombus Dissolving Agent amid Re-Prioritization Drive
December 5, 2017
- ASKA Expands Testosterone Deal with TesoRx Pharma
December 5, 2017
- Pfizer Sues Meiji Seika Pharma, Claiming Infringement of Zyvox Patent
December 5, 2017
- Takeda Spin-Off Chordia Aims to Develop Oncology Blockbuster Drug
December 4, 2017
- Ayumi Looks to Haul in Over 10 Billion Yen from 3 RA Biosimilars: President
December 1, 2017
- Hiroshima Univ. Spinoff Initiates PIII Study for Regenerative Cellular Medicine for Chondrogenesis in Knee
December 1, 2017
- Novartis to Keep Close Eye on Discussions on Clozaril at Chuikyo, Expects Strengthened Measures to Promote Proper Use
November 30, 2017
- Pfizer Lifts Shipment Adjustments of 3 Brands/4 Products after Resuming Operations at Hurricane-Hit Plant in Puerto Rico
November 30, 2017
- Takeda Launches PI Study of Zika Vaccine Candidate
November 30, 2017
- Japan’s 1st Rituxan Biosimilar to Arrive Soon, Sandoz Confident on Market Acquisition
November 29, 2017
- MSD, Astellas to Copromote Januvia-Suglat Combo
November 29, 2017
- Nichi-Iko Rolls Out Remicade Biosimilar
November 29, 2017
- Clozaril Tablets 25 mg Temporarily in Short Supply due to Troubles at Overseas Plant
November 29, 2017
- Kyowa Kirin Gains Rights to NHE3 Inhibitor in Japan
November 29, 2017
- Stefan Woxström Tapped as New AZ Japan President Effective Jan. 2018
November 28, 2017
- EA Pharma Files Constipation Drug AJG555 in Japan
November 28, 2017
- Santen Files Omidenepag Isopropyl for Glaucoma, Ocular Hypertension in Japan
November 28, 2017
- Tagrisso Filed for 1st-Line EGFR-Mutated NSCLC in Japan: AZ
November 28, 2017
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…